Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2012

01-07-2012 | Clinical Trial

Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer

Authors: David W. Cescon, Patricia A. Ganz, Samantha Beddows, Marguerite Ennis, Barbara K. Mills, Pamela J. Goodwin

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Login to get access

Abstract

Low serum vitamin D levels have been associated with poor outcomes in women diagnosed with early breast cancer. However, no randomized controlled trials (RCTs) have been performed to determine whether vitamin D supplementation might be an effective intervention in this population. We prospectively evaluated vitamin D adequacy and supplementation rates in a contemporary cross-sectional sample of breast cancer patients from 2 large urban centers and examined the feasibility of an RCT of vitamin D supplementation. Women with recently diagnosed early breast cancer were prospectively identified and recruited in Toronto and Los Angeles between March 2009 and January 2010. Anthropometric measurements, dietary, lifestyle, and medication histories were obtained by means of structured questionnaires and interviews. Tumor and treatment characteristics were abstracted from clinical records and blood samples were collected for analysis of 25-OH vitamin D. 173 eligible patients (median age 57) were enrolled. Clinical and treatment characteristics were similar between centres. 84.4 % of women reported use of vitamin D-containing supplements with median daily doses of 1,400 IU. Median 25-OH vitamin D levels were 85.5 and 98.5 nmol/L (P = 0.1), and levels of deficiency (<50 nmol/L), insufficiency (50–72 nmol/L), and adequacy (>72 nmol/L) were 3.8, 23.8, 72.5 % (Toronto) and 4.3, 20.7, 75 % (Los Angeles). 25-OH vitamin D levels were strongly correlated with vitamin D supplement use (r = 0.41, P < 0.0001). 68 % of women expressed willingness to participate in a vitamin D supplementation RCT; however, only 12.7 % of the study population met the pre-specified feasibility criteria (25-OH vitamin D <72 nmol/L, willing to participate, and taking ≤1,000 IU vitamin D supplement/day). Both vitamin D levels and supplementation rates are higher than in previous reports. While the majority of women would be willing to participate in an RCT of vitamin D supplementation, low levels of deficiency/insufficiency and high rates of supplement use would limit the feasibility of such a study.
Appendix
Available only for authorised users
Literature
2.
go back to reference Institute of Medicine (2011) Dietary reference intakes for calcium and vitamin D. National Academies Press, Washington DC Institute of Medicine (2011) Dietary reference intakes for calcium and vitamin D. National Academies Press, Washington DC
4.
go back to reference Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85:1586–1591PubMed Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85:1586–1591PubMed
10.
go back to reference Vrieling A, Hein R, Abbas S et al (2011) Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res 13:R74. doi:10.1186/bcr2920 PubMedCrossRef Vrieling A, Hein R, Abbas S et al (2011) Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res 13:R74. doi:10.​1186/​bcr2920 PubMedCrossRef
13.
go back to reference Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA et al (2010) Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 172:81–93. doi:10.1093/aje/kwq120 PubMedCrossRef Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA et al (2010) Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 172:81–93. doi:10.​1093/​aje/​kwq120 PubMedCrossRef
15.
go back to reference Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622–629. doi:10.1002/humu.20495 PubMedCrossRef Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622–629. doi:10.​1002/​humu.​20495 PubMedCrossRef
16.
go back to reference Lippman SM, Klein EA, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39–51. doi:10.1001/jama.2008.864 PubMedCrossRef Lippman SM, Klein EA, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39–51. doi:10.​1001/​jama.​2008.​864 PubMedCrossRef
19.
go back to reference Block G, Hartman AM, Dresser CM et al (1986) A data-based approach to diet questionnaire design and testing. Am J Epidemiol 124:453–469PubMed Block G, Hartman AM, Dresser CM et al (1986) A data-based approach to diet questionnaire design and testing. Am J Epidemiol 124:453–469PubMed
21.
go back to reference Statistics Canada (2010) Canadian Health Measures Survey: Cycle 1 2007 to 2009. 82-623-X, no. 2 Statistics Canada (2010) Canadian Health Measures Survey: Cycle 1 2007 to 2009. 82-623-X, no. 2
22.
go back to reference Hadji P, Aapro MS, Body JJ et al (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol. doi:10.1093/annonc/mdr017 PubMed Hadji P, Aapro MS, Body JJ et al (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol. doi:10.​1093/​annonc/​mdr017 PubMed
26.
go back to reference Khan QJ, Reddy PS, Kimler BF et al (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119:111–118. doi:10.1007/s10549-009-0495-x PubMedCrossRef Khan QJ, Reddy PS, Kimler BF et al (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119:111–118. doi:10.​1007/​s10549-009-0495-x PubMedCrossRef
Metadata
Title
Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer
Authors
David W. Cescon
Patricia A. Ganz
Samantha Beddows
Marguerite Ennis
Barbara K. Mills
Pamela J. Goodwin
Publication date
01-07-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2120-7

Other articles of this Issue 2/2012

Breast Cancer Research and Treatment 2/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine